Wanda Filer, MD, MBA

The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.

Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.

The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.

An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.

Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.

Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.

As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.

Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.

Experts on RSV vaccination discuss shared decision-making practices and the importance of getting at-risk patients vaccinated.

The expert panel discusses ways to increase awareness of the RSV vaccine for patients who would benefit from it.

Focusing on the diagnosis of RSV, Mary Bridgeman, PharmD, BCPS, BCGP, provides clinical insights on signs and symptoms and testing practices.

A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.

Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.

Marty J. Feltner, PharmD, provides insights on complications associated with RSV infections and how complications vary for different patient populations.

A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.